PDF(Pubmed)
Abstract：
UNASSIGNED: The risk of periprosthetic joint infection (PJI) subsequently developing at a second site after an initial PJI has been documented to be approximately 18%-20%. To the best of our knowledge, only a single study has evaluated the incidence in ipsilateral joints and if the risk of infection would be different. While this was the only other study to evaluate this specific subfield, we set to re-evaluate and confirm the incidence of developing a second PJI in the setting of an ipsilateral prosthesis and possible associated risk factors.
UNASSIGNED: We retrospectively reviewed all patients treated surgically for lower-extremity PJI at our institution by 5 surgeons from 2015 to 2021. Patients with multiple arthroplasties on the ipsilateral extremity were included. Time between initial and subsequent infection, risk factors for infection, bacterial source, and bacteremia were identified.
UNASSIGNED: Of 392 patients treated for PJI, 179 (45.6%) had multiple prosthetic joints. Forty-seven of those 179 patients had ipsilateral extremity prosthesis, which made up our study population. Three patients (6.4%) developed a separate infection at an ipsilateral TJA. In total, 10 patients (21.3%) developed a separate PJI. Patients on immunosuppressants had a higher likelihood of developing second PJI on the ipsilateral extremity (P = .02).
UNASSIGNED: Our study identified the risk of developing an ipsilateral PJI to not be any greater than that in patients with contralateral TJAs. It appears that sharing an extremity with an infected TJA does not pose substantially increased risk of subsequent infection of the un-involved prosthesis. Furthermore, immunosuppressant use may increase the risk of a separate ipsilateral PJI.
UNASSIGNED: We retrospectively reviewed all patients treated surgically for lower-extremity PJI at our institution by 5 surgeons from 2015 to 2021. Patients with multiple arthroplasties on the ipsilateral extremity were included. Time between initial and subsequent infection, risk factors for infection, bacterial source, and bacteremia were identified.
UNASSIGNED: Of 392 patients treated for PJI, 179 (45.6%) had multiple prosthetic joints. Forty-seven of those 179 patients had ipsilateral extremity prosthesis, which made up our study population. Three patients (6.4%) developed a separate infection at an ipsilateral TJA. In total, 10 patients (21.3%) developed a separate PJI. Patients on immunosuppressants had a higher likelihood of developing second PJI on the ipsilateral extremity (P = .02).
UNASSIGNED: Our study identified the risk of developing an ipsilateral PJI to not be any greater than that in patients with contralateral TJAs. It appears that sharing an extremity with an infected TJA does not pose substantially increased risk of subsequent infection of the un-involved prosthesis. Furthermore, immunosuppressant use may increase the risk of a separate ipsilateral PJI.
摘要：
■在初始PJI之后,随后在第二部位发展的假体周围关节感染(PJI)的风险已被证明为约18%-20%。据我们所知,只有一项研究评估了同侧关节的发病率以及感染风险是否不同.虽然这是评估这个特定子场的唯一另一项研究，我们将重新评估并确认在同侧假体中发生第二次PJI的发生率以及可能的相关危险因素.
■我们回顾性回顾了2015年至2021年在我们机构由5名外科医生进行的下肢PJI手术治疗的所有患者。包括同侧肢体多次关节置换术的患者。最初和随后感染之间的时间，感染的危险因素，细菌来源，和菌血症被确认。
■在接受PJI治疗的392名患者中，179（45.6％）有多个假体关节。这179例患者中有47例患有同侧四肢假体，构成了我们的研究人群。三名患者（6.4％）在同侧TJA发生了单独的感染。总的来说,10名患者(21.3%)发展为单独的PJI。使用免疫抑制剂的患者在同侧肢体发生第二PJI的可能性更高（P=.02）。
■我们的研究发现，发生同侧PJI的风险不大于对侧TJAs患者的风险。似乎与受感染的TJA共享四肢不会大大增加未受累假体随后感染的风险。此外，使用免疫抑制剂可能会增加单独同侧PJI的风险.
■我们回顾性回顾了2015年至2021年在我们机构由5名外科医生进行的下肢PJI手术治疗的所有患者。包括同侧肢体多次关节置换术的患者。最初和随后感染之间的时间，感染的危险因素，细菌来源，和菌血症被确认。
■在接受PJI治疗的392名患者中，179（45.6％）有多个假体关节。这179例患者中有47例患有同侧四肢假体，构成了我们的研究人群。三名患者（6.4％）在同侧TJA发生了单独的感染。总的来说,10名患者(21.3%)发展为单独的PJI。使用免疫抑制剂的患者在同侧肢体发生第二PJI的可能性更高（P=.02）。
■我们的研究发现，发生同侧PJI的风险不大于对侧TJAs患者的风险。似乎与受感染的TJA共享四肢不会大大增加未受累假体随后感染的风险。此外，使用免疫抑制剂可能会增加单独同侧PJI的风险.
